What is Breztri Aerosphere?
Breztri Aerosphere is a triple-combination inhaler containing budesonide, a corticosteroid, glycopyrrolate, an anticholinergic, and formoterol fumarate, a long-acting beta-agonist [1][2]. It is prescribed for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD) [1].
What is the patent status for Breztri Aerosphere?
The patent status for Breztri Aerosphere, specifically concerning its budesonide component, involves multiple patents. AstraZeneca holds patents related to the formulation and use of Breztri Aerosphere [3]. Key patents protecting the drug and its delivery system are set to expire at different times [3]. For example, some patents have expiration dates extending into the late 2030s [3].
When do Breztri Aerosphere patents expire?
The expiration dates for patents covering Breztri Aerosphere vary. For instance, U.S. Patent No. 10,407,303, which relates to the Aerosphere device, is listed with an expiration date of November 23, 2035 [3]. Other patents covering the combination drug product may have different expiration timelines [3].
Can generic or biosimilar versions of Breztri Aerosphere enter the market before patent expiry?
Generally, the entry of generic or biosimilar versions of a drug is restricted until the expiration of relevant patents and any granted market exclusivity periods [4]. Companies may seek to invalidate or circumvent existing patents to launch generics earlier [4]. However, Breztri Aerosphere's patent protection, particularly for its specific formulation and delivery device, aims to prevent early generic competition [3][4].
Why are companies challenging patents for drugs like Breztri Aerosphere?
Companies often challenge patents for branded drugs like Breztri Aerosphere to pave the way for the introduction of lower-cost generic alternatives [4]. These challenges can take the form of patent litigation, seeking to invalidate existing patents or argue that their own products do not infringe upon them [4]. Successfully challenging patents can lead to significant market opportunities for generic manufacturers [4].
What are the risks associated with Breztri Aerosphere?
Like all medications, Breztri Aerosphere carries potential risks and side effects. Common side effects can include nasopharyngitis, pneumonia, bronchitis, oral candidiasis, and hoarseness [1]. More serious risks include an increased risk of pneumonia in patients with COPD, paradoxical bronchospasm, and effects related to the corticosteroid component, such as reduced bone mineral density and ocular effects [1]. Patients are advised to discuss any concerns with their healthcare provider [1].
How does Breztri Aerosphere compare to other COPD treatments?
Breztri Aerosphere offers a triple combination therapy for COPD, which may provide benefits for patients whose symptoms are not adequately controlled with dual bronchodilators or with inhaled corticosteroids and a long-acting beta2-agonist [1][5]. Other COPD treatments include single-agent bronchodilators (long-acting muscarinic antagonists or long-acting beta2-agonists), dual bronchodilators, and inhaled corticosteroid/long-acting beta2-agonist combinations [5]. The specific choice of treatment depends on the individual patient's disease severity, symptom burden, and response to therapy [5].
What clinical data supports Breztri Aerosphere's efficacy?
Clinical trials have demonstrated the efficacy of Breztri Aerosphere in improving lung function and reducing exacerbations in patients with COPD [2][6]. For example, the TRIUMPH and KRONOS studies showed that Breztri Aerosphere significantly reduced the rate of moderate or severe COPD exacerbations compared to dual bronchodilator therapy [2][6].
Who makes Breztri Aerosphere?
Breztri Aerosphere is developed and manufactured by AstraZeneca [1].
What are patients asking about Breztri Aerosphere?
Patients often inquire about the effectiveness of Breztri Aerosphere in managing their COPD symptoms, potential side effects such as oral thrush or voice changes, and how it compares to their current medications [1]. They may also ask about the proper technique for using the Aerosphere inhaler to ensure they receive the full dose [1].
---
Cited Sources
[1] https://www.breztri.com/
[2] https://www.astrazeneca.com/media-centre/press-releases/2019/astrazenecas-breztri-aerosphere-triple-therapy-approved-in-the-eu-for-patients-with-copd-10092019.html
[3] https://www.accessdata.fda.gov/scripts/drugdb/prototype/monograph/patents.cfm?k=10037230
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6274953/
[5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8076216/
[6] https://www.globenewswire.com/news-release/2019/03/20/1757771/0/en/AstraZeneca-s-BREZTRI-AEROSPHERE-TRIPLE-THERAPY-meets-primary-endpoint-in-Phase-III-KRONOS-trial-for-COPD.html